DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Neuropeptide Y is an investigational drug.
There have been 4 clinical trials for Neuropeptide Y. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, and Disease. The leading clinical trial sponsors are Westchester Medical Center, U.S. Army Medical Research and Development Command, and Vanderbilt University.
There are two hundred and sixty-two US patents protecting this investigational drug and three international patents.
Recent Clinical Trials for Neuropeptide Y
|Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder||U.S. Army Medical Research and Development Command||Phase 1/Phase 2|
|Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder||Westchester Medical Center||Phase 1/Phase 2|
|Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder||New York Medical College||Phase 1/Phase 2|
Top disease conditions for Neuropeptide Y
Top clinical trial sponsors for Neuropeptide Y
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Neuropeptide Y||Start Trial||Neuropeptide Y-derived peptides||University of Copenhagen (Copenhagen K, DK) N.ae butted.stved Hospital (N.ae butted.stved, DK)||Start Trial|
|Neuropeptide Y||Start Trial||Methods for the treatment of kidney fibrosis||THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, MA)||Start Trial|
|Neuropeptide Y||Start Trial||Method using an Y1 receptor activator for treating an anticancer agent-induced nephrotoxic injury||KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR)||Start Trial|
|Neuropeptide Y||Start Trial||Diagnostic method for diagnosing depression and monitoring therapy effectiveness||BRAINLABS B.V. (NL) RIJKSUNIVERSITEIT GRONINGEN (NL) ACADEMISCH ZIEKENHUIS GRONINGEN (NL)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Neuropeptide Y||Denmark||2983690||2033-04-10||Start Trial|
|Neuropeptide Y||European Patent Office||2983690||2033-04-10||Start Trial|
|Neuropeptide Y||Spain||2729970||2033-04-10||Start Trial|
|Neuropeptide Y||Poland||2983690||2033-04-10||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|